| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 9.2 | 29.7 |
| Net income | -40.7 | -61.9 |
| EPS (diluted, $ a share) | $-0.62 | $-1.20 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -69.2% |
|---|---|
| Operating margin | -387.8% |
10-Q filed with the SEC, NASDAQ: RGNX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Regenxbio Inc.: key numbers
- Share price
- $7.32Close, Nov 16
- Market cap
- $484M
- Shares outstanding
- 66.12MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Regenxbio Inc.
All →Regenxbio Financial Results
REGENXBIO reported Q3 2026 financial results, highlighting progress toward a BLA submission for its Duchenne muscular dystrophy gene therapy RGX-202 in Q1 2027. The company also expects topline pivotal data for its wet AMD candidate sura-vec in Q4 2026, with global regulatory submissions planned for 2027.
“We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027 and 2028. With topline pivotal data expected this quarter, sura-vec has the potential to transform the treatment paradigm for a broad spectrum of patients with wet AMD. We also remain on track for the RGX-202 BLA submission early next year as we work toward delivering this important therapy to Duchenne patients as quickly as possible. We remain focused on executing these near-term milestones and leveraging our fully integrated capabilities to deliver meaningful new treatment options for patients.”
Curran Simpson, President and Chief Executive Officer of REGENXBIO
Regenxbio Leadership Change
Kenneth T. Mills resigned from the board of directors of REGENXBIO Inc. effective October 21, 2026, to focus on his new role as CEO of another company. In response, the board appointed George Migausky as the new Chairman of the Board, while Daniel Tassé stepped down as Lead Independent Director but remains on the board.
Regenxbio Court & Legal Update
REGENXBIO and UPenn entered into a settlement agreement with Sarepta Therapeutics and Catalent to resolve all patent infringement litigation regarding U.S. Patent Nos. 10,526,617 and 11,680,274. Sarepta will pay REGENXBIO $39.0 million and receive a covenant not to sue for future claims relating to gene therapy products using an AAVrh74-based capsid, including ELEVIDYS.
- Counterparty
- Sarepta Therapeutics, Inc.